In ZINC since | Heavy atoms | Benign functionality |
---|---|---|
October 4th, 2005 | 20 | Yes |
Popular Name: Apigenin Apigenin
Find On: PubMed — Wikipedia — Google
CAS Numbers: 263711-74-6 , 520-36-5 , 8002-66-2 , [520-36-5]
4',5,7-Trihydroxyflavone; 5,7,4'-Trihydroxyflavone; 520-36-5; Apigenin; C01477
4',5,7-Trihydroxyflavone; 520-36-5; CPD-431; apigenin
5,7-Dihydroxy-2-(4-hydroxy-phenyl)-chromen-4-one
5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
520-36-5; Apigenin; Prestwick_719
Apigenin with HPLC [520-36-5]; (5,7,4'-Trihydroxyflavone)
Apigenin [520-36-5]; (5,7,4'-Trihydroxyflavone)
Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
---|---|---|---|---|---|---|---|---|---|---|
Ref Reference (pH 7) | 2.46 | 1.12 | -12.82 | 3 | 5 | 0 | 91 | 270.24 | 1 | ↓ |
Mid Mid (pH 6-8) | 2.72 | 1.4 | -45.92 | 2 | 5 | -1 | 94 | 269.232 | 1 | ↓ |
Note Type | Comments | Provided By |
---|---|---|
biological_source | Found free or as glycosides in the stems, roots, leaves, seeds or fruit of a very wide range of plant spp. Found also in some fossil leaf tissues | ZereneX Building Blocks |
biological_use | Shows antineoplastic activity in vitro | ZereneX Building Blocks |
ALOGPS_SOLUBILITY | 1.18e-01 g/l | DrugBank-experimental |
MP | 345 - 350 °C | Fluorochem |
MP | 345-350o C | Indofine |
MP | 355-358o C | Indofine |
M.P. | >350C (dec) | Indofine |
Purity | >95% | Fluorochem |
therap | antispasmodic, antineoplastic, topoisomerase I inhibitor | MicroSource Spectrum |
biological_use | Antispasmolytic agent | IBScreen Bioactives |
Melting_Point | ca 315? dec. | Alfa-Aesar |
Melting_Point | ca 315° dec. | Alfa-Aesar |
Patent Database Links | EP1523982; EP1550462; EP1600061; EP1808169; EP1808172; EP1834636; EP1842541; EP1911358; EP1925311; US2002048798; US2006135585; US2007184133; US2007191330; US2007202195; US2007212393; US2007224296; US2007232698; US2008262080; WO2005020981; WO2006121518; WO | ChEBI |
UniProt Database Links | FNSI_PETCR; FOMT2_WHEAT; GBA3_HUMAN; I7GT1_SOYBN; OMT15_ORYSJ; OMT17_ORYSJ; OMT1_CHRAE; OMT2_CHRAE; SOMT2_SOYBN; SOT5_ARATH; TPS3_MATRE; U73B2_ARATH; UBGAT_SCUBA; UGFGT_MEDTR | ChEBI |
UniProt Database Links | FNSI_PETCR; FOMT2_WHEAT; GBA3_HUMAN; I7GT1_SOYBN; OMT15_ORYSJ; OMT17_ORYSJ; OMT1_CHRAE; OMT2_CHRAE; SOMT2_SOYBN; SOT5_ARATH; U73B2_ARATH; UBGAT_SCUBA; UGFGT_MEDTR | ChEBI |
Target | G1/S-specific cyclin-D1(P24385)&Cyclin-dependent kinase inhibitor 1(P38936)&Cell division protein kinase 4(P11802)&NAD(P)H dehydrogenase [quinone] 1(P15559)&DNA topoisomerase 1(P11387)&Transcription factor AP-1(P05412)&Cyclic AMP-responsive element-bindin | Herbal Ingredients Targets |
Target | P450 | Selleck Chemicals |
biological_use | Shows antineoplastic activity in vitro | IBScreen Bioactives IBScreen Bioactives |
SOLUBILITY | Soluble in Ethylformiate/acetone/toluene | Indofine |
SOLUBILITY | Soluble in Methanol | Indofine |
mechanism | Tyrosine kinase inhibitor | IBScreen Bioactives |
APPEARANCE | Yellow crystals | Indofine |
Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
AA1R-2-E | Adenosine A1 Receptor (cluster #2 Of 4), Eukaryotic | Eukaryotes | 3000 | 0.39 | Binding ≤ 10μM |
AA2AR-3-E | Adenosine A2a Receptor (cluster #3 Of 4), Eukaryotic | Eukaryotes | 7580 | 0.36 | Binding ≤ 10μM |
ABCG2-1-E | ATP-binding Cassette Sub-family G Member 2 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 5900 | 0.37 | Binding ≤ 10μM |
ALDR-1-E | Aldose Reductase (cluster #1 Of 5), Eukaryotic | Eukaryotes | 6670 | 0.36 | Binding ≤ 10μM |
AOFA-4-E | Monoamine Oxidase A (cluster #4 Of 8), Eukaryotic | Eukaryotes | 1700 | 0.40 | Binding ≤ 10μM |
BGLR-1-E | Beta-glucuronidase (cluster #1 Of 2), Eukaryotic | Eukaryotes | 2800 | 0.39 | Binding ≤ 10μM |
CCNB1-1-E | G2/mitotic-specific Cyclin B1 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 4000 | 0.38 | Binding ≤ 10μM |
CCNB2-1-E | G2/mitotic-specific Cyclin B2 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 4000 | 0.38 | Binding ≤ 10μM |
CCNB3-1-E | G2/mitotic-specific Cyclin B3 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 4000 | 0.38 | Binding ≤ 10μM |
CDK1-1-E | Cyclin-dependent Kinase 1 (cluster #1 Of 4), Eukaryotic | Eukaryotes | 4000 | 0.38 | Binding ≤ 10μM |
CDK6-1-E | Cyclin-dependent Kinase 6 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 1700 | 0.40 | Binding ≤ 10μM |
CP19A-3-E | Cytochrome P450 19A1 (cluster #3 Of 3), Eukaryotic | Eukaryotes | 900 | 0.42 | Binding ≤ 10μM |
CP1B1-1-E | Cytochrome P450 1B1 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 25 | 0.53 | Binding ≤ 10μM |
CSK21-2-E | Casein Kinase II Alpha (cluster #2 Of 3), Eukaryotic | Eukaryotes | 800 | 0.43 | Binding ≤ 10μM |
CSK2B-3-E | Casein Kinase II Beta (cluster #3 Of 3), Eukaryotic | Eukaryotes | 4290 | 0.38 | Binding ≤ 10μM |
DHB1-1-E | Estradiol 17-beta-dehydrogenase 1 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 710 | 0.43 | Binding ≤ 10μM |
ESR1-1-E | Estrogen Receptor Alpha (cluster #1 Of 5), Eukaryotic | Eukaryotes | 660 | 0.43 | Binding ≤ 10μM |
ESR2-4-E | Estrogen Receptor Beta (cluster #4 Of 4), Eukaryotic | Eukaryotes | 660 | 0.43 | Binding ≤ 10μM |
GBRA1-1-E | GABA Receptor Alpha-1 Subunit (cluster #1 Of 8), Eukaryotic | Eukaryotes | 3020 | 0.39 | Binding ≤ 10μM |
GBRA2-1-E | GABA Receptor Alpha-2 Subunit (cluster #1 Of 8), Eukaryotic | Eukaryotes | 3020 | 0.39 | Binding ≤ 10μM |
GBRA3-1-E | GABA Receptor Alpha-3 Subunit (cluster #1 Of 8), Eukaryotic | Eukaryotes | 3020 | 0.39 | Binding ≤ 10μM |
GBRA4-1-E | GABA Receptor Alpha-4 Subunit (cluster #1 Of 7), Eukaryotic | Eukaryotes | 3020 | 0.39 | Binding ≤ 10μM |
GBRA5-1-E | GABA Receptor Alpha-5 Subunit (cluster #1 Of 8), Eukaryotic | Eukaryotes | 3020 | 0.39 | Binding ≤ 10μM |
GBRA6-6-E | GABA Receptor Alpha-6 Subunit (cluster #6 Of 8), Eukaryotic | Eukaryotes | 3020 | 0.39 | Binding ≤ 10μM |
GSK3A-1-E | Glycogen Synthase Kinase-3 Alpha (cluster #1 Of 3), Eukaryotic | Eukaryotes | 1400 | 0.41 | Binding ≤ 10μM |
GSK3B-7-E | Glycogen Synthase Kinase-3 Beta (cluster #7 Of 7), Eukaryotic | Eukaryotes | 1400 | 0.41 | Binding ≤ 10μM |
MRP1-1-E | Multidrug Resistance-associated Protein 1 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 2400 | 0.39 | Binding ≤ 10μM |
NOX4-1-E | NADPH Oxidase 4 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 1130 | 0.42 | Binding ≤ 10μM |
P90584-1-E | Protein Kinase Pfmrk (cluster #1 Of 2), Eukaryotic | Eukaryotes | 7000 | 0.36 | Binding ≤ 10μM |
PGH2-4-E | Cyclooxygenase-2 (cluster #4 Of 8), Eukaryotic | Eukaryotes | 8000 | 0.36 | Binding ≤ 10μM |
XDH-2-E | Xanthine Dehydrogenase (cluster #2 Of 2), Eukaryotic | Eukaryotes | 700 | 0.43 | Binding ≤ 10μM |
ANDR-1-E | Androgen Receptor (cluster #1 Of 3), Eukaryotic | Eukaryotes | 5200 | 0.37 | Functional ≤ 10μM |
CP1A1-1-E | Cytochrome P450 1A1 (cluster #1 Of 3), Eukaryotic | Eukaryotes | 427 | 0.45 | ADME/T ≤ 10μM |
CP1A2-1-E | Cytochrome P450 1A2 (cluster #1 Of 3), Eukaryotic | Eukaryotes | 795 | 0.43 | ADME/T ≤ 10μM |
CP1B1-1-E | Cytochrome P450 1B1 (cluster #1 Of 3), Eukaryotic | Eukaryotes | 64 | 0.50 | ADME/T ≤ 10μM |
Z104294-2-O | Cyclin-dependent Kinase 5/CDK5 Activator 1 (cluster #2 Of 2), Other | Other | 1600 | 0.41 | Binding ≤ 10μM |
Z104301-4-O | GABA-A Receptor; Anion Channel (cluster #4 Of 8), Other | Other | 770 | 0.43 | Binding ≤ 10μM |
Z50597-1-O | Rattus Norvegicus (cluster #1 Of 12), Other | Other | 3400 | 0.38 | Functional ≤ 10μM |
Z50607-3-O | Human Immunodeficiency Virus 1 (cluster #3 Of 10), Other | Other | 9000 | 0.35 | Functional ≤ 10μM |
Z50652-3-O | Influenza A Virus (cluster #3 Of 4), Other | Other | 4740 | 0.37 | Functional ≤ 10μM |
Z80418-2-O | RAW264.7 (Monocytic-macrophage Leukemia Cells) (cluster #2 Of 9), Other | Other | 7700 | 0.36 | Functional ≤ 10μM |
Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
CSK21_HUMAN | P68400 | Casein Kinase II Alpha, Human | 740 | 0.43 | Binding ≤ 1μM |
CP19A_HUMAN | P11511 | Cytochrome P450 19A1, Human | 1000 | 0.42 | Binding ≤ 1μM |
CP1B1_HUMAN | Q16678 | Cytochrome P450 1B1, Human | 25 | 0.53 | Binding ≤ 1μM |
DHB1_HUMAN | P14061 | Estradiol 17-beta-dehydrogenase 1, Human | 710 | 0.43 | Binding ≤ 1μM |
ESR1_HUMAN | P03372 | Estrogen Receptor Alpha, Human | 660 | 0.43 | Binding ≤ 1μM |
ESR2_HUMAN | Q92731 | Estrogen Receptor Beta, Human | 130 | 0.48 | Binding ≤ 1μM |
Z104301 | Z104301 | GABA-A Receptor; Anion Channel | 770 | 0.43 | Binding ≤ 1μM |
XDH_HUMAN | P47989 | Xanthine Dehydrogenase, Human | 700 | 0.43 | Binding ≤ 1μM |
AA1R_RAT | P25099 | Adenosine A1 Receptor, Rat | 3000 | 0.39 | Binding ≤ 10μM |
AA2AR_RAT | P30543 | Adenosine A2a Receptor, Rat | 7580 | 0.36 | Binding ≤ 10μM |
ALDR_RAT | P07943 | Aldose Reductase, Rat | 6670 | 0.36 | Binding ≤ 10μM |
ABCG2_HUMAN | Q9UNQ0 | ATP-binding Cassette Sub-family G Member 2, Human | 3100 | 0.39 | Binding ≤ 10μM |
BGLR_RAT | P06760 | Beta-glucuronidase, Rat | 2800 | 0.39 | Binding ≤ 10μM |
CSK21_HUMAN | P68400 | Casein Kinase II Alpha, Human | 10000 | 0.35 | Binding ≤ 10μM |
CSK2B_HUMAN | P67870 | Casein Kinase II Beta, Human | 10000 | 0.35 | Binding ≤ 10μM |
CDK1_HUMAN | P06493 | Cyclin-dependent Kinase 1, Human | 4000 | 0.38 | Binding ≤ 10μM |
Z104294 | Z104294 | Cyclin-dependent Kinase 5/CDK5 Activator 1 | 1600 | 0.41 | Binding ≤ 10μM |
CDK6_HUMAN | Q00534 | Cyclin-dependent Kinase 6, Human | 1700 | 0.40 | Binding ≤ 10μM |
PGH2_HUMAN | P35354 | Cyclooxygenase-2, Human | 8000 | 0.36 | Binding ≤ 10μM |
CP19A_HUMAN | P11511 | Cytochrome P450 19A1, Human | 1000 | 0.42 | Binding ≤ 10μM |
CP1B1_HUMAN | Q16678 | Cytochrome P450 1B1, Human | 25 | 0.53 | Binding ≤ 10μM |
DHB1_HUMAN | P14061 | Estradiol 17-beta-dehydrogenase 1, Human | 710 | 0.43 | Binding ≤ 10μM |
ESR1_HUMAN | P03372 | Estrogen Receptor Alpha, Human | 1253 | 0.41 | Binding ≤ 10μM |
ESR2_HUMAN | Q92731 | Estrogen Receptor Beta, Human | 130 | 0.48 | Binding ≤ 10μM |
CCNB1_HUMAN | P14635 | G2/mitotic-specific Cyclin B1, Human | 4000 | 0.38 | Binding ≤ 10μM |
CCNB2_HUMAN | O95067 | G2/mitotic-specific Cyclin B2, Human | 4000 | 0.38 | Binding ≤ 10μM |
CCNB3_HUMAN | Q8WWL7 | G2/mitotic-specific Cyclin B3, Human | 4000 | 0.38 | Binding ≤ 10μM |
GBRA1_HUMAN | P14867 | GABA Receptor Alpha-1 Subunit, Human | 3019.95172 | 0.39 | Binding ≤ 10μM |
GBRA2_HUMAN | P47869 | GABA Receptor Alpha-2 Subunit, Human | 3019.95172 | 0.39 | Binding ≤ 10μM |
GBRA3_HUMAN | P34903 | GABA Receptor Alpha-3 Subunit, Human | 3019.95172 | 0.39 | Binding ≤ 10μM |
GBRA4_HUMAN | P48169 | GABA Receptor Alpha-4 Subunit, Human | 3019.95172 | 0.39 | Binding ≤ 10μM |
GBRA5_HUMAN | P31644 | GABA Receptor Alpha-5 Subunit, Human | 3019.95172 | 0.39 | Binding ≤ 10μM |
GBRA6_HUMAN | Q16445 | GABA Receptor Alpha-6 Subunit, Human | 3019.95172 | 0.39 | Binding ≤ 10μM |
Z104301 | Z104301 | GABA-A Receptor; Anion Channel | 770 | 0.43 | Binding ≤ 10μM |
GSK3A_HUMAN | P49840 | Glycogen Synthase Kinase-3 Alpha, Human | 1400 | 0.41 | Binding ≤ 10μM |
GSK3B_HUMAN | P49841 | Glycogen Synthase Kinase-3 Beta, Human | 1400 | 0.41 | Binding ≤ 10μM |
AOFA_HUMAN | P21397 | Monoamine Oxidase A, Human | 1700 | 0.40 | Binding ≤ 10μM |
MRP1_HUMAN | P33527 | Multidrug Resistance-associated Protein 1, Human | 2400 | 0.39 | Binding ≤ 10μM |
NOX4_HUMAN | Q9NPH5 | NADPH Oxidase 4, Human | 1130 | 0.42 | Binding ≤ 10μM |
P90584_PLAFA | P90584 | Protein Kinase Pfmrk, Plafa | 7000 | 0.36 | Binding ≤ 10μM |
XDH_HUMAN | P47989 | Xanthine Dehydrogenase, Human | 700 | 0.43 | Binding ≤ 10μM |
ANDR_HUMAN | P10275 | Androgen Receptor, Human | 5200 | 0.37 | Functional ≤ 10μM |
Z50607 | Z50607 | Human Immunodeficiency Virus 1 | 9000 | 0.35 | Functional ≤ 10μM |
Z50652 | Z50652 | Influenza A Virus | 4740 | 0.37 | Functional ≤ 10μM |
Z50597 | Z50597 | Rattus Norvegicus | 3400 | 0.38 | Functional ≤ 10μM |
Z80418 | Z80418 | RAW264.7 (Monocytic-macrophage Leukemia Cells) | 500 | 0.44 | Functional ≤ 10μM |
CP1A1_HUMAN | P04798 | Cytochrome P450 1A1, Human | 390 | 0.45 | ADME/T ≤ 10μM |
CP1A2_HUMAN | P05177 | Cytochrome P450 1A2, Human | 795 | 0.43 | ADME/T ≤ 10μM |
CP1B1_HUMAN | Q16678 | Cytochrome P450 1B1, Human | 64 | 0.50 | ADME/T ≤ 10μM |
Description | Species |
---|---|
Abacavir transmembrane transport | |
ABC-family proteins mediated transport | |
Activation of NIMA Kinases NEK9, NEK6, NEK7 | |
Adenosine P1 receptors | |
Aflatoxin activation and detoxification | |
AKT phosphorylates targets in the cytosol | |
APC truncation mutants have impaired AXIN binding | |
APC/C:Cdc20 mediated degradation of Cyclin B | |
Aromatic amines can be N-hydroxylated or N-dealkylated by CYP1A2 | |
AXIN missense mutants destabilize the destruction complex | |
Beta-catenin phosphorylation cascade | |
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | |
Cobalamin (Cbl, vitamin B12) transport and metabolism | |
Condensation of Prometaphase Chromosomes | |
Condensation of Prophase Chromosomes | |
Constitutive PI3K/AKT Signaling in Cancer | |
CRMPs in Sema3A signaling | |
Cyclin A/B1 associated events during G2/M transition | |
Cyclin B2 mediated events | |
Cyclin D associated events in G1 | |
Degradation of beta-catenin by the destruction complex | |
Depolymerisation of the Nuclear Lamina | |
disassembly of the destruction complex and recruitment of AXIN to the membrane | |
E2F mediated regulation of DNA replication | |
E2F-enabled inhibition of pre-replication complex formation | |
Endogenous sterols | |
Enzymatic degradation of dopamine by COMT | |
Enzymatic degradation of Dopamine by monoamine oxidase | |
ERK1 activation | |
Estrogen biosynthesis | |
G alpha (i) signalling events | |
G alpha (s) signalling events | |
G0 and Early G1 | |
G1/S-Specific Transcription | |
G2/M DNA replication checkpoint | |
GABA A receptor activation | |
Golgi Cisternae Pericentriolar Stack Reorganization | |
Iron uptake and transport | |
Ligand-gated ion channel transport | |
Loss of Nlp from mitotic centrosomes | |
Loss of proteins required for interphase microtubule organization from the ce | |
MASTL Facilitates Mitotic Progression | |
Metabolism of serotonin | |
Methylation | |
misspliced GSK3beta mutants stabilize beta-catenin | |
Monoamines are oxidized to aldehydes by MAOA and MAOB, producing NH3 and H2O2 | |
NGF-independant TRKA activation | |
Nicotinamide salvaging | |
Norepinephrine Neurotransmitter Release Cycle | |
Nuclear Pore Complex (NPC) Disassembly | |
Nuclear Receptor transcription pathway | |
Nuclear signaling by ERBB4 | |
Oncogene Induced Senescence | |
Oxidative Stress Induced Senescence | |
Phosphorylation of Emi1 | |
Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 com | |
Phosphorylation of the APC/C | |
Polo-like kinase mediated events | |
PPARA activates gene expression | |
Pregnenolone biosynthesis | |
Purine catabolism | |
Recruitment of mitotic centrosome proteins and complexes | |
Recruitment of NuMA to mitotic centrosomes | |
Regulation of APC/C activators between G1/S and early anaphase | |
Regulation of HSF1-mediated heat shock response | |
Regulation of PLK1 Activity at G2/M Transition | |
Resolution of Sister Chromatid Cohesion | |
S33 mutants of beta-catenin aren't phosphorylated | |
S37 mutants of beta-catenin aren't phosphorylated | |
S45 mutants of beta-catenin aren't phosphorylated | |
Senescence-Associated Secretory Phenotype (SASP) | |
Signal transduction by L1 | |
Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE) | |
Synthesis of 15-eicosatetraenoic acid derivatives | |
Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET) | |
Synthesis of Leukotrienes (LT) and Eoxins (EX) | |
Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | |
T41 mutants of beta-catenin aren't phosphorylated | |
The canonical retinoid cycle in rods (twilight vision) | |
truncations of AMER1 destabilize the destruction complex | |
WNT mediated activation of DVL | |
XBP1(S) activates chaperone genes | |
Xenobiotics |
No pre-computed analogs available. Try a structural similarity search.